These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31369458)

  • 1. Changes in the Matrix Metalloproteinase 9 Point-of-Care Test Positivity According to MMP-9 Concentration and Loading Volume.
    Huh J; Choi SY; Eom Y; Kim HM; Song JS
    Cornea; 2020 Feb; 39(2):234-236. PubMed ID: 31369458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes.
    Chan TC; Ye C; Chan KP; Chu KO; Jhanji V
    Br J Ophthalmol; 2016 Sep; 100(9):1188-91. PubMed ID: 26682569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of tear volume for positivity of tear matrix metalloproteinase-9 immunoassay.
    Jun JH; Lee YH; Son MJ; Kim H
    PLoS One; 2020; 15(7):e0235408. PubMed ID: 32649686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease.
    Sambursky R; Davitt WF; Friedberg M; Tauber S
    Cornea; 2014 Aug; 33(8):812-8. PubMed ID: 24977985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A preliminary study on the tear matrix metalloproteinase 9 point-of-care assay using a domestic kit].
    Wan XC; Zhang H; Shen Y; Zhou SY; Yang P; Zhou XJ; Gu H; Le QH; Xu JJ; Zhou XT; Hong JX
    Zhonghua Yan Ke Za Zhi; 2023 Apr; 59(4):272-278. PubMed ID: 37012590
    [No Abstract]   [Full Text] [Related]  

  • 8. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.
    Sambursky R; Davitt WF; Latkany R; Tauber S; Starr C; Friedberg M; Dirks MS; McDonald M
    JAMA Ophthalmol; 2013 Jan; 131(1):24-8. PubMed ID: 23307206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay.
    Bang SP; Son MJ; Kim H; Lee YH; Jun JH
    Sci Rep; 2020 Sep; 10(1):15126. PubMed ID: 32934302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.
    Lanza NL; McClellan AL; Batawi H; Felix ER; Sarantopoulos KD; Levitt RC; Galor A
    Ocul Surf; 2016 Apr; 14(2):216-23. PubMed ID: 26807724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of tear matrix metalloproteinase 9 immunoassay with signs and symptoms of dry eye disease: A cross-sectional study using qualitative, semiquantitative, and quantitative strategies.
    Lee YH; Bang SP; Shim KY; Son MJ; Kim H; Jun JH
    PLoS One; 2021; 16(10):e0258203. PubMed ID: 34662364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tear MMP-9 levels as a marker of ocular surface inflammation in conjunctivochalasis.
    Acera A; Vecino E; Duran JA
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8285-91. PubMed ID: 24255042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.
    Lanza NL; Valenzuela F; Perez VL; Galor A
    Ocul Surf; 2016 Apr; 14(2):189-95. PubMed ID: 26850527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomous versus 5-scale grading system for the interpretation of the point-of-care immunoassay for tear matrix metalloproteinase-9 in dry eye.
    Oh JY; Chun YS; Kim KW
    Sci Rep; 2023 Apr; 13(1):6085. PubMed ID: 37055446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Ramadan daytime fasting with ocular surface inflammation and dry eye.
    Armstrong BK; Coc IR; Agarwal P; Smith S; Navon S
    Int Ophthalmol; 2019 Dec; 39(12):2857-2863. PubMed ID: 31152289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications.
    Kaufman HE
    Cornea; 2013 Feb; 32(2):211-6. PubMed ID: 22673852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tear Martix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Post-Lasik Ectasia.
    Elmohamady MN; Abdelghaffar W; Salem TI
    Int Ophthalmol; 2019 Mar; 39(3):631-637. PubMed ID: 29478225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunoassay for matrix metalloproteinase-9 in the tear film of patients with pseudoexfoliation syndrome - a pilot study].
    Zimmermann N; Erb C
    Klin Monbl Augenheilkd; 2013 Aug; 230(8):804-7. PubMed ID: 23670526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in tear biomarker levels in keratoconus after corneal collagen crosslinking.
    Recalde JI; Duran JA; Rodriguez-Agirretxe I; Soria J; Sanchez-Tena MA; Pereiro X; Suarez T; Acera A
    Mol Vis; 2019; 25():12-21. PubMed ID: 30804658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of galectin-3 in tears of patients with dry eye disease.
    Uchino Y; Mauris J; Woodward AM; Dieckow J; Amparo F; Dana R; Mantelli F; Argüeso P
    Am J Ophthalmol; 2015 Jun; 159(6):1027-1035.e3. PubMed ID: 25703476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.